PURPOSE: Patients with recurrence after complete resection of colorectal liver metastases (CLM) are considered for repeat resection as a potential salvage therapy (PST). However, outcomes for this approach are not well defined. We sought to analyze the natural history of recurrence and PST in a large cohort of patients with long-term follow-up. METHODS: Recurrence patterns, treatments, and outcomes in consecutive patients undergoing resection for colorectal liver metastases were analyzed retrospectively. PST was defined as repeat resection of all recurrent disease and effective salvage therapy (EST) as free of disease for 36 months after last PST. Factors associated with PST, EST, and outcomes were analyzed. RESULTS: Of 952 patients who underwent resection, 594 (62 %) experienced recurrence (median interval = 13 months). Initial recurrences involved liver (n = 157,26 %), lung (n = 167,28 %), multiple sites (n = 171,29 %), and other single sites (n = 99,17 %). PST was performed in 160 (27 %) of 594, most commonly with a single site of recurrence (n = 149). Young age (p = 0.01), negative initial resection margin (p = 0.003), initial tumor size <5 cm (p = 0.006), and recurrence pattern (p < 0.001) were independently associated with PST. Thirty-six patients experienced EST (25 % of PSTs). Overall median survival was 61 and 43 months in those with recurrence. Median survival of patients undergoing PST was 87 months compared to 34 months for those who did not. CONCLUSIONS: Recurrence is common after CLM resection, but 27 % of patients were able to undergo PST. Approximately one-quarter of these experienced EST and may be cured. PST is associated with long-term survival and possible cure, and therefore active surveillance after CLM resection is justified.
PURPOSE:Patients with recurrence after complete resection of colorectal liver metastases (CLM) are considered for repeat resection as a potential salvage therapy (PST). However, outcomes for this approach are not well defined. We sought to analyze the natural history of recurrence and PST in a large cohort of patients with long-term follow-up. METHODS: Recurrence patterns, treatments, and outcomes in consecutive patients undergoing resection for colorectal liver metastases were analyzed retrospectively. PST was defined as repeat resection of all recurrent disease and effective salvage therapy (EST) as free of disease for 36 months after last PST. Factors associated with PST, EST, and outcomes were analyzed. RESULTS: Of 952 patients who underwent resection, 594 (62 %) experienced recurrence (median interval = 13 months). Initial recurrences involved liver (n = 157,26 %), lung (n = 167,28 %), multiple sites (n = 171,29 %), and other single sites (n = 99,17 %). PST was performed in 160 (27 %) of 594, most commonly with a single site of recurrence (n = 149). Young age (p = 0.01), negative initial resection margin (p = 0.003), initial tumor size <5 cm (p = 0.006), and recurrence pattern (p < 0.001) were independently associated with PST. Thirty-six patients experienced EST (25 % of PSTs). Overall median survival was 61 and 43 months in those with recurrence. Median survival of patients undergoing PST was 87 months compared to 34 months for those who did not. CONCLUSIONS: Recurrence is common after CLM resection, but 27 % of patients were able to undergo PST. Approximately one-quarter of these experienced EST and may be cured. PST is associated with long-term survival and possible cure, and therefore active surveillance after CLM resection is justified.
Authors: Anthony Antoniou; Richard E Lovegrove; Henry S Tilney; Alexander G Heriot; Timothy G John; Myrddin Rees; Paris P Tekkis; Fenella K S Welsh Journal: Surgery Date: 2006-11-17 Impact factor: 3.982
Authors: Dimitrios Moris; Sean Ronnekleiv-Kelly; Amir A Rahnemai-Azar; Evangelos Felekouras; Mary Dillhoff; Carl Schmidt; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2017-03-31 Impact factor: 3.452
Authors: Eric P van der Stok; Manon C W Spaander; Dirk J Grünhagen; Cornelis Verhoef; Ernst J Kuipers Journal: Nat Rev Clin Oncol Date: 2016-12-20 Impact factor: 66.675
Authors: E P van der Stok; M Smid; A M Sieuwerts; P B Vermeulen; S Sleijfer; N Ayez; D J Grünhagen; J W M Martens; C Verhoef Journal: Mol Oncol Date: 2016-09-20 Impact factor: 6.603
Authors: Markus Zimmermann; Federico Pedersoli; Maximilian Schulze-Hagen; Georg Lurje; Peter Isfort; Christiane Kuhl; Philipp Bruners Journal: Eur Radiol Date: 2019-09-06 Impact factor: 5.315
Authors: Nancy E Kemeny; Joanne F Chou; Taryn M Boucher; Marinela Capanu; Ronald P DeMatteo; William R Jarnagin; Peter J Allen; Yuman C Fong; Andrea Cercek; Michael I D'Angelica Journal: J Surg Oncol Date: 2016-02-02 Impact factor: 3.454